At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
LGVN Longeveron Inc
Closed Good Friday 04-17 16:00:00 EDT
1.46
+0.05
+3.55%
盘后1.40
-0.06-4.10%
18:58 EDT
| High1.49 | Low1.37 | Vol86.66K |
| Open1.43 | D1 Closing1.41 | Amplitude8.51% |
| Mkt Cap21.79M | Tradable Cap17.92M | Total Shares14.93M |
| T/O125.70K | T/O Rate0.71% | Tradable Shares12.28M |
| P/B-- | ROE-- | EPS0.00 |
| 52wk High-- | 52wk Low-- | P/E-- |
| Dividend-- | Div.Yield-- | ROA-- |
Loading ...
Longeveron Files $70 Million Mixed Shelf
MT Newswires Live · 03-28
BRIEF-Longeveron Inc Files For Mixed Shelf Of Up To $70 Million - SEC Filing
Reuters · 03-28
Longeveron Inc Files for Mixed Shelf of up to $70 Mln - SEC Filing
THOMSON REUTERS · 03-28
Longeveron’s Promising Alzheimer’s Program: Buy Rating Backed by FDA Alignment and Strategic Advancements
TIPRANKS · 03-22
Longeveron Price Target Maintained With a $10.00/Share by HC Wainwright & Co.
Dow Jones · 03-21
Longeveron Inc: Company Anticipates Initiating Pivotal Clinical Trial in Second Half of 2026
THOMSON REUTERS · 03-20
Longeveron® Announces Positive Type B Meeting With U.S. FDA Regarding Pathway to Bla for Laromestrocel (Lomecel-Btm) in Alzheimer’s Disease
THOMSON REUTERS · 03-20
Longeveron® Announces Positive Type B Meeting with U.S. FDA Regarding Pathway to BLA for Laromestrocel (Lomecel-BTM) in Alzheimer’s Disease
GlobeNewswire · 03-20
LGVN Announces Positive Alzheimer’s News
Zacks Small Cap Research · 03-20
Roth MKM Keeps Their Buy Rating on Longeveron (LGVN)
TIPRANKS · 03-11
Longeveron® Announces Nature Medicine Publication Of Results Of Phase 2A Clinical Trial Evaluating Laromestrocel (Lomecel-B™) In Alzheimer’S Disease
Reuters · 03-11
Longeveron® Announces Nature Medicine Publication of Results of Phase 2a Clinical Trial Evaluating Laromestrocel (Lomecel-B™) in Alzheimer’s Disease
GlobeNewswire · 03-11
Longeveron’s Clinical Advancements and Strategic Positioning Earn a Buy Rating
TIPRANKS · 03-05
Longeveron® to Present at the 37th Annual Roth Conference
GlobeNewswire · 03-05
Roth MKM Sticks to Its Buy Rating for Longeveron (LGVN)
TIPRANKS · 03-04
Longeveron Inc. Earnings Call: Growth and Challenges
TIPRANKS · 03-04
Promising Outlook for Longeveron: ELPIS II Trial Progress and Financial Strength Highlighted
TIPRANKS · 03-03
LGVN Well Positioned for Critical 2025
Zacks Small Cap Research · 03-03
Analysts Expect Breakeven For Longeveron Inc. (NASDAQ:LGVN) Before Long
Simply Wall St. · 03-02
Longeveron Full Year 2024 Earnings: Beats Expectations
Simply Wall St. · 03-02
Introduction
Company Name.
Longeveron Inc
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company's lead investigational product is the LOMECEL-B, a candidate in Phase 2a/b trials that is used for the treatment of alzheimer's disease, hypoplastic left heart syndrome, and aging-related frailty. The company was incorporated in 2014 and is headquartered in Miami, Florida.
Issue price:
--
Invest in Global Markets with Tiger Brokers!Open App